Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2022, with a report date of February 17, 2022. The document serves as a notification regarding the vesting of Conditional Share Awards under the Share Value Plan for Persons Discharging Managerial Responsibilities (PDMRs) and their closely associated persons (PCAs). The awards, granted in 2019 and conditional on continued employment, vested on February 14, 2022. The filing also details the subsequent sale of Ordinary Shares and American Depositary Shares (ADSs) by these individuals to meet tax liabilities.
Key Financial Metrics
This filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific equity transactions involving executive compensation.
| Executive / Role | Instrument | Transaction Type | Volume | Price | Date |
|---|---|---|---|---|---|
| Ms S Ramakrishnan (Chief Digital and Technology Officer) | ADSs | Vesting | 7,654 | $0.00 | 2022-02-13 |
| Ms S Ramakrishnan | ADSs | Sale (Tax) | 4,104 | $42.9532 | 2022-02-14 |
| Ms D Waterhouse (CEO, ViiV Healthcare) | Ordinary Shares | Vesting | 13,780 | £0.00 | 2022-02-13 |
| Ms D Waterhouse | Ordinary Shares | Sale (Tax) | 6,477 | £15.8987 | 2022-02-14 |
| Ms V Whyte (Company Secretary) | Ordinary Shares | Vesting | 13,070 | £0.00 | 2022-02-13 |
| Ms V Whyte | Ordinary Shares | Sale (Tax) | 6,143 | £15.8987 | 2022-02-14 |
| Mr D Jackson (PCA of Ms S Jackson) | Ordinary Shares | Vesting | 6,330 | £0.00 | 2022-02-13 |
| Mr D Jackson | Ordinary Shares | Sale (Tax) | 2,976 | £15.8987 | 2022-02-14 |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It documents routine equity compensation events (vesting and tax-related sales) for specific executives as scheduled under the 2019 Share Value Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transactions were executed on the New York Stock Exchange (for ADSs) and the London Stock Exchange (for Ordinary Shares) to satisfy tax obligations arising from the vesting of awards.
Key Facts for Investor Verification
- Transaction Nature: All reported sales were executed specifically to meet tax liabilities on vested awards, not as discretionary open-market sales.
- Participants: Transactions involved Ms S Ramakrishnan, Ms D Waterhouse, Ms V Whyte, and Mr D Jackson (PCA).
- Timing: Vesting occurred on February 13, 2022, with sales executed on February 14, 2022.
- Financial Impact: This filing does not reflect GSK's corporate financial performance; investors should refer to Form 20-F or quarterly earnings releases for revenue and profit data.